These findings suggest that combining a Src inhibitor such as saracatinib (AZD0530) with the FDA-approved MEK1/2 inhibitor trametinib may eradicate dormant breast tumor cells before they awaken (Figure 2). The gene discussed is SRC; the disease is breast neoplasm.